Intercept Pharmaceuticals (NASDAQ:ICPT) Stock Rating Upgraded by Raymond James

Raymond James upgraded shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from an outperform rating to a strong-buy rating in a research note released on Monday, February 4th, MarketBeat.com reports. Raymond James currently has $184.00 price target on the biopharmaceutical company’s stock.

Several other research analysts also recently commented on ICPT. Credit Suisse Group assumed coverage on shares of Intercept Pharmaceuticals in a research note on Thursday, January 31st. They issued an outperform rating and a $167.00 target price on the stock. JMP Securities raised shares of Intercept Pharmaceuticals from a market perform rating to an outperform rating and lifted their target price for the stock from $75.00 to $175.00 in a research note on Wednesday, January 30th. Jefferies Financial Group lifted their target price on shares of Intercept Pharmaceuticals to $150.00 and gave the stock a buy rating in a research note on Monday, January 28th. Needham & Company LLC raised shares of Intercept Pharmaceuticals from a hold rating to a buy rating and set a $150.00 price objective on the stock in a research report on Thursday, January 24th. Finally, UBS Group started coverage on shares of Intercept Pharmaceuticals in a research report on Wednesday, January 23rd. They issued a buy rating and a $130.00 target price on the stock. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and sixteen have assigned a buy rating to the company’s stock. Intercept Pharmaceuticals has a consensus rating of Buy and an average price target of $144.57.

NASDAQ ICPT traded up $6.95 during trading hours on Monday, reaching $106.69. 1,859,543 shares of the company were exchanged, compared to its average volume of 1,357,262. The company has a market capitalization of $2.77 billion, a PE ratio of -9.82 and a beta of 1.88. The company has a debt-to-equity ratio of 3.83, a quick ratio of 5.98 and a current ratio of 5.98. Intercept Pharmaceuticals has a 1 year low of $58.03 and a 1 year high of $133.74.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Thursday, February 28th. The biopharmaceutical company reported ($2.97) EPS for the quarter, missing analysts’ consensus estimates of ($2.42) by ($0.55). Intercept Pharmaceuticals had a negative net margin of 202.93% and a negative return on equity of 645.54%. The firm had revenue of $53.30 million during the quarter, compared to the consensus estimate of $52.53 million. During the same quarter last year, the business posted ($4.43) earnings per share. Intercept Pharmaceuticals’s revenue was up 41.4% compared to the same quarter last year. As a group, analysts forecast that Intercept Pharmaceuticals will post -7.93 EPS for the current fiscal year.

In related news, EVP Christian Weyer sold 333 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $103.16, for a total value of $34,352.28. Following the completion of the sale, the executive vice president now directly owns 19,440 shares in the company, valued at $2,005,430.40. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider David Shapiro sold 2,000 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $103.16, for a total value of $206,320.00. Following the completion of the sale, the insider now owns 42,543 shares of the company’s stock, valued at $4,388,735.88. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 38,558 shares of company stock valued at $4,632,917. Insiders own 4.90% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc lifted its position in shares of Intercept Pharmaceuticals by 2.8% during the third quarter. Vanguard Group Inc now owns 1,952,931 shares of the biopharmaceutical company’s stock worth $246,772,000 after purchasing an additional 54,038 shares during the last quarter. Strs Ohio lifted its position in shares of Intercept Pharmaceuticals by 30.0% during the fourth quarter. Strs Ohio now owns 1,300 shares of the biopharmaceutical company’s stock worth $131,000 after purchasing an additional 300 shares during the last quarter. Macquarie Group Ltd. lifted its position in shares of Intercept Pharmaceuticals by 158.8% during the third quarter. Macquarie Group Ltd. now owns 35,561 shares of the biopharmaceutical company’s stock worth $4,493,000 after purchasing an additional 21,819 shares during the last quarter. AQR Capital Management LLC purchased a new position in shares of Intercept Pharmaceuticals during the third quarter valued at $2,764,000. Finally, Intercontinental Wealth Advisors LLC purchased a new position in shares of Intercept Pharmaceuticals during the fourth quarter valued at $34,000. Institutional investors and hedge funds own 65.00% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

Featured Article: Quiet Period Expirations Explained

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply